A Study to Determine the Safety and Efficacy of Famciclovir in the Episodic and Suppressive Treatment of Recurrent Genital Herpes (RGH). The Study Will Also Evaluate Quality of Life and Patient Satisfaction.

Trial Profile

A Study to Determine the Safety and Efficacy of Famciclovir in the Episodic and Suppressive Treatment of Recurrent Genital Herpes (RGH). The Study Will Also Evaluate Quality of Life and Patient Satisfaction.

Completed
Phase of Trial: Phase IV

Latest Information Update: 26 Apr 2012

At a glance

  • Drugs Famciclovir (Primary)
  • Indications Herpes genitalis
  • Focus Therapeutic Use
  • Acronyms RELIEF
  • Sponsors Novartis
  • Most Recent Events

    • 26 Apr 2012 Actual end date (Jun 2005) added as reported by ClinicalTrials.gov.
    • 26 Apr 2012 Actual initiation date (Jun 2003) added as reported by ClinicalTrials.gov.
    • 26 Apr 2012 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health; NCT00219310).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top